This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Chinook Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Chinook Therapeutics kazanç ve gelirinin sırasıyla yıllık 22.6% ve 63.8% oranında artması tahmin edilirken, EPS'nin yıllık 28% oranında büyümesi bekleniyor.

Anahtar bilgiler

22.6%

Kazanç büyüme oranı

27.96%

EPS büyüme oranı

Biotechs kazanç büyümesi	25.3%
Gelir büyüme oranı	63.8%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	10 Aug 2023

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • May 28

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Feb 14

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Aug 31

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Summary Shares have risen by 50% since coming public via reverse merger in 2020. Lead drug atrasentan has shown promising reductions in proteinuria that exceed approved treatment Tarpeyo. Competition in IgAN should not be underestimated from the likes of Travere Therapeutics, Vera Therapeutics and other peers. BION-1301 offers them a second shot on goal with superior potency. Key readouts for both assets are approaching in 2023. KDNY is a Buy and I suggest accumulating dips to high-teens. Key risks include emerging competition in IgAN as well as disappointing pivotal readout for atrasentan.

Analiz Makalesi • Aug 12

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

One thing we could say about the analysts on Chinook Therapeutics, Inc. ( NASDAQ:KDNY ) - they aren't optimistic...

Seeking Alpha • Aug 08

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Chinook Therapeutics press release (NASDAQ:KDNY): Q2 GAAP EPS of -$0.61 in-line. Revenue of $0.42M (+1300.0% Y/Y) in-line.

Seeking Alpha • Jul 05

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

Chinook Therapeutics (NASDAQ:KDNY) on Tuesday said it had got European orphan drug designation for its BION-1301 treatment for primary IgA nephropathy, a type of kidney disease. The European drug regulator's orphan designation is given to medicines developed for rare, life-threatening diseases. The orphan drug designation for BION-1301 follows a positive opinion from a European drug regulator committee. KDNY will be evaluating BION-1301 in a phase 3 study in 2023. KDNY stock closed largely unchanged at $17.51 on Friday.

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:KDNY - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	80	-247	-286	-253	8
12/31/2024	13	-284	-289	-262	11
12/31/2023	3	-253	-290	-243	5
6/30/2023	6	-246	-177	-174	N/A
3/31/2023	5	-216	-146	-143	N/A
12/31/2022	6	-188	-119	-117	N/A
9/30/2022	57	-118	-105	-103	N/A
6/30/2022	54	-92	-104	-103	N/A
3/31/2022	54	-97	-101	-99	N/A
12/31/2021	52	-103	-105	-103	N/A
9/30/2021	1	-160	-124	-122	N/A
6/30/2021	1	-149	-105	-104	N/A
3/31/2021	1	-114	-82	-80	N/A
12/31/2020	1	-82	-57	-56	N/A
9/30/2020	N/A	-52	-19	-19	N/A
6/30/2020	N/A	-54	-17	-16	N/A
3/31/2020	N/A	-48	-16	-15	N/A
12/31/2019	N/A	-47	-14	-14	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: KDNY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: KDNY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: KDNY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: KDNY şirketinin gelirinin (yıllık 63.8% ) US pazarından (yıllık 11.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: KDNY şirketinin gelirinin (yıllık 63.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: KDNY 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2023/08/12 10:42
Gün Sonu Hisse Fiyatı	2023/08/10 00:00
Kazançlar	2023/06/30
Yıllık Kazançlar	2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Chinook Therapeutics, Inc. 11 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Antonia Borovina	Bloom Burton & Co.
Charles Duncan	Cantor Fitzgerald & Co.
Joshua Schimmer	Evercore ISI

This company has been acquired

Chinook Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 7.8% to US$39.45

Consensus revenue estimates increase by 36%

Consensus revenue estimates increase by 273%

Consensus revenue estimates increase by 27%, EPS downgraded

Consensus forecasts updated

Consensus revenue estimates fall by 14%

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Price target increased by 7.8% to US$39.45

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

New major risk - Share price stability

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

Consensus revenue estimates increase by 36%

Consensus revenue estimates increase by 273%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

President notifies of intention to sell stock

Independent Lead Director recently sold US$6.1m worth of stock

Chief Scientific Officer exercised options and sold US$57k worth of stock

Consensus revenue estimates increase by 27%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$192k worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

President recently sold US$190k worth of stock

Chief Scientific Officer exercised options and sold US$191k worth of stock

Chief Operating Officer exercised options and sold US$246k worth of stock

President exercised options and sold US$657k worth of stock

Consensus forecasts updated

Chief Operating Officer notifies of intention to sell stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Operating Officer exercised options and sold US$217k worth of stock

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Chief Operating Officer exercised options and sold US$145k worth of stock

Independent Director recently bought US$212k worth of stock

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Consensus revenue estimates fall by 14%

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Chief Scientific Officer exercised options and sold US$98k worth of stock

Chief Scientific Officer exercised options and sold US$89k worth of stock

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

High number of new directors

President recently bought US$65k worth of stock

Consensus forecasts updated

Price target increased to US$34.86

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chief Scientific Officer exercised options and sold US$75k worth of stock

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları